Overall impact
B (75)

Commentary

Exicure is a strong overall performer. With a 'B' rating of 75.0 for overall impact (89th percentile compared to all companies), Exicure ranks 147th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 143 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 435 others. On top material causes for Exicure's industry (Pharmaceuticals & Biotech), Exicure performs well in Child and Maternal Health (89.8 score), Reduced Use of tobacco (95.5), Sustainable Use of Water (95.4) and 6 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (33.2 score), Reduced Green House Gas Emissions (33.2) and Disaster Readiness and Effective Aid (33.6).
Impact
Cause XCUR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
XCUR
Description
Exicure, Inc. does not have significant operations. Previously, the company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Material causes
Ethos considers the following causes material for Exicure, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.